Research dossier
Clinical research on Ginkgo
8 trials reviewed across 5 indications.
Strongest evidence
Cognitive symptoms in existing dementia
Mechanism
Improved cerebral blood flow and antioxidant protection of neurons are the proposed routes for symptomatic, rather than disease-modifying, benefit.
In people who already have dementia, 240 mg/day produced modest cognitive benefits in some trials (Le Bars 1997), but the 2009 Cochrane review of 36 trials called the overall evidence 'inconsistent and unreliable.' A small symptomatic effect is possible; it is not dependable, and the best trials are negative.
At best a modest adjunct in diagnosed dementia, never a substitute for medical treatment. The positive trials are smaller and often industry-funded; the larger and independent ones are null.
Trials cited
North American EGb Study — ginkgo in dementia
positive · RCT
Le Bars et al., 1997, JAMAn=309Industry-fundedThe trial most often cited by ginkgo marketers. Showed a modest cognitive benefit (~1.4 ADAS-Cog points) in established dementia over a year — small but measurable. High dropout (about half) weakens confidence in the result.
Manufacturer-funded (Schwabe). ~50% dropout and a small absolute effect. A modest symptomatic effect in existing dementia is a very different claim than prevention or cognitive enhancement.
Cochrane review — ginkgo for cognitive impairment and dementia
mixed · Systematic review
Birks & Grimley Evans, 2009, Cochrane Database of Systematic Reviewsn=2016Pooled 36 trials and concluded the evidence that ginkgo has predictable, clinically significant benefit for dementia or cognitive impairment is 'inconsistent and unreliable.' Some early trials were positive; the larger, better trials were not. Ginkgo was as safe as placebo.
Heterogeneous trials with high risk of bias and publication bias in the older, smaller, often industry-sponsored studies. The honest read is signal-without-reliability.
Dementia prevention
Mechanism
Proposed via antioxidant scavenging, improved cerebral microcirculation, and platelet-activating-factor inhibition by ginkgolides — all plausible on paper.
This is the headline claim, and it is refuted. Two large, long, independently funded RCTs — GEM (n=3069, 6 years) and GuidAge (n=2854, 5 years) — both found ginkgo does not prevent dementia or Alzheimer's. When the hypothesis got a fair test, it failed twice.
No population benefits from ginkgo for dementia prevention based on the two definitive trials. Do not take ginkgo to prevent cognitive decline.
GEM — Ginkgo Evaluation of Memory study
negative · RCT
DeKosky et al., 2008, JAMAn=3069The largest, longest ginkgo trial ever run. Over a median 6.1 years, 277 of 1545 ginkgo users developed dementia vs 246 of 1524 on placebo — no reduction, if anything numerically worse. Ginkgo does not prevent dementia in older adults.
NIH-funded and independently run — this is not a manufacturer trial that can be waved away. The negative result is robust.
GuidAge — long-term ginkgo for Alzheimer's prevention
negative · RCT
Vellas et al., 2012, Lancet Neurologyn=2854Second large independent prevention trial. Over 5 years, 61 of the ginkgo group converted to Alzheimer's vs 73 on placebo — not statistically significant. Long-term ginkgo did not lower the risk of progressing from memory complaints to Alzheimer's disease.
Government-funded (French health authorities). A post-hoc 'on-treatment' analysis hinted at benefit, but the pre-specified intention-to-treat result was null — and post-hoc subgroup signals are not evidence of efficacy.
Memory and focus in healthy people
Mechanism
Marketed as a nootropic that sharpens memory and concentration in normal adults.
The 'brain boost' positioning is unsupported. A clean independent RCT (Solomon 2002) gave healthy older adults the label dose and found zero benefit on memory, attention, or language. A systematic review concluded ginkgo 'is not a smart drug.' If you are cognitively healthy, ginkgo will not make you sharper.
No demonstrated cognitive benefit in cognitively normal adults of any age.
Ginkgo for memory enhancement in healthy older adults
Null · RCT
Solomon et al., 2002, JAMAn=230Took the marketing claim at face value — gave healthy older adults ginkgo at the label dose and tested memory. No benefit on any measure of memory, attention, or language vs placebo. Ginkgo is not a memory enhancer for cognitively normal people.
Independently funded (National Institute on Aging, HHMI). Short 6-week duration, but the cognition-enhancement claim is specifically a short-term one, so the design is fair to the hypothesis.
Systematic review — ginkgo as a nootropic in healthy people
Null · Systematic review
Canter & Ernst, 2007, Human PsychopharmacologyReviewed the randomized trials of ginkgo as a 'smart drug' in healthy people and found no convincing evidence of a robust positive effect on any aspect of cognition, after either single doses or longer-term use. Titled, bluntly, that ginkgo 'is not a smart drug.'
Consistent with later meta-analyses (e.g. Laws 2012) reaching the same null conclusion in healthy adults.
Peripheral circulation and claudication
Mechanism
Ginkgolides inhibit platelet-activating factor and the extract modestly improves microcirculation — the rationale for a peripheral-blood-flow benefit.
The 2013 Cochrane review of 14 trials (739 people) found any improvement in pain-free walking distance was small and not clinically significant. The circulation mechanism is real but does not translate into a meaningful functional benefit for peripheral arterial disease.
Not a substitute for supervised exercise therapy or vascular medical management in claudication.
Cochrane review — ginkgo for intermittent claudication
Null · Systematic review
Nicolaï et al., 2013, Cochrane Database of Systematic Reviewsn=739Pooled 14 trials (739 participants). Any improvement in walking distance over placebo was small and not clinically significant. Despite ginkgo's plausible circulation mechanism, it does not meaningfully help people with claudication walk further.
Small, heterogeneous trials. The mechanistic story (improved microcirculation) is real but does not translate to a clinically useful walking-distance benefit.
Tinnitus
Mechanism
Proposed via improved cochlear blood flow and neuroprotection of auditory pathways.
A common OTC use that the evidence does not back. The 2022 Cochrane review of 12 studies (1,915 people) concluded ginkgo probably does not reduce tinnitus severity or loudness when ringing in the ears is the primary complaint.
No reliable benefit for primary subjective tinnitus.
Cochrane review — ginkgo for tinnitus
Null · Systematic review
Sereda et al., 2022, Cochrane Database of Systematic Reviewsn=1915Pooled 12 studies (1,915 people). Ginkgo probably does not reduce the severity or loudness of tinnitus in adults whose main complaint is ringing in the ears. A common folk and OTC use that the controlled evidence does not support.
Low-to-moderate certainty evidence; consistent direction across trials. The popular 'ginkgo for ringing ears' claim is not backed by the trial record.
2 forms of Ginkgo compared
EGb 761® (Tebonin/Tanakan); also Schwabe extract
Standardized leaf extract (EGb 761 / 24-6)
The clinically tested form
Best forEvery major RCT — GEM, GuidAge, Le Bars — used a standardized extract delivering ~24% flavone glycosides and ~6% terpene lactonesIf a product is not standardized to 24/6 (or does not say 'EGb 761'), it has not been tested at all — the trial evidence does not transfer to crude leaf powder or unstandardized extracts.
cognition120–240 mgCrude ginkgo leaf / unstandardized powder
Unknown — not the tested form
Best forCheap filler in some multi-herb blendsActive compound content is uncontrolled and ginkgolic acids (allergenic, potentially genotoxic) may not be removed. The standardized EGb 761 trials say nothing about crude leaf.
Are you deficient? Symptoms, risk groups, lab tests
Side effects and drug interactions
Side effects
Bleeding and bruising
Uncommon
Ginkgolides inhibit platelet-activating factor, reducing platelet aggregation. Spontaneous bleeding events (including rare intracranial and ocular bleeds) have been reported, mostly when combined with anticoagulants or antiplatelets.
Headache and dizziness
Common
Most common mild complaints, more frequent at higher doses and on initiation.
Gastrointestinal upset
Common
Nausea, diarrhea, or stomach discomfort, usually mild.
Allergic / skin reactions
Uncommon
Rash and itching. Ginkgo is related to poison ivy (Anacardiaceae-adjacent chemistry); ginkgolic acids in poorly processed extracts are the usual culprit.
Seizure threshold lowering
Rare
Ginkgo seeds contain ginkgotoxin (4'-O-methylpyridoxine); high intake or contaminated extracts may lower seizure threshold. Relevant for people with epilepsy.
Drug interactions
Combined-effect risk
warfarinapixabanrivaroxabanaspirinclopidogrelNSAIDsGinkgo's antiplatelet activity adds to that of anticoagulant and antiplatelet drugs, raising bleeding risk.
Avoid combining without physician oversight. Stop ginkgo at least 1–2 weeks before any surgery or dental procedure.
Other
SSRIsMAO inhibitorsGinkgo may modulate monoamine systems; combination with serotonergic drugs has theoretical serotonin-related risk.
Use caution and tell your prescriber if combining with antidepressants.
Other
anticonvulsants (valproate, carbamazepine, phenytoin)Ginkgotoxin content may lower seizure threshold and could undercut anticonvulsant control.
People with epilepsy should avoid ginkgo.
Reduces nutrient status
efavirenzomeprazolesome statinsGinkgo induces CYP enzymes (notably CYP2C19 and CYP3A4) and may lower plasma levels of drugs cleared by these pathways.
Discuss with a pharmacist if you take narrow-therapeutic-index medications metabolized by CYP2C19/3A4.
Other critical caveats
- Ginkgo does NOT prevent dementia. Two large, long, independently funded trials (GEM 2008, n=3069, 6 years; GuidAge 2012, n=2854, 5 years) tested exactly this claim and both came back negative. Marketing that implies otherwise is contradicted by the best available evidence.
- Ginkgo is not a cognitive enhancer for healthy people. The independent Solomon 2002 RCT and the Canter & Ernst review found no memory or focus benefit in cognitively normal adults.
- The trial evidence applies only to the standardized EGb 761 (24% flavone glycosides / 6% terpene lactones) extract. Crude leaf powder or unstandardized extracts have not been studied and may contain allergenic ginkgolic acids.
- Bleeding risk is the headline safety issue. Stop ginkgo 1–2 weeks before surgery and use caution with anticoagulants, antiplatelets, and NSAIDs.
- People with epilepsy should avoid ginkgo — ginkgotoxin can lower seizure threshold.
Frequently asked
Does ginkgo biloba prevent dementia or Alzheimer's?
No. This is the most-tested ginkgo claim and it failed. The GEM study (3,069 older adults, 6 years) and the GuidAge study (2,854 older adults, 5 years) were both large, long, and independently funded — and both found ginkgo did not prevent dementia or Alzheimer's disease versus placebo. Do not rely on ginkgo for cognitive protection.Will ginkgo make me sharper or improve my memory?
Not if you are cognitively healthy. An independent JAMA trial (Solomon 2002) gave healthy older adults the label dose for 6 weeks and found no benefit on memory, attention, or language. A systematic review concluded ginkgo 'is not a smart drug.' The nootropic positioning is marketing, not evidence.Is ginkgo completely useless then?
Not completely. In people who already have dementia, some trials (Le Bars 1997) showed a small symptomatic cognitive benefit at 240 mg/day, though the larger Cochrane review called the overall evidence 'inconsistent and unreliable.' That is a modest, unreliable, symptom-level effect in a diagnosed condition — a far weaker claim than prevention or enhancement.What dose and form should I use if I take it anyway?
Only the standardized extract studied in trials: 120–240 mg/day of an extract standardized to ~24% flavone glycosides and ~6% terpene lactones (EGb 761 is the reference). Crude leaf powder has never been tested and may contain allergenic, potentially harmful ginkgolic acids.Is ginkgo safe with my medications?
The main concern is bleeding. Ginkgo inhibits platelet aggregation, so combining it with warfarin, DOACs, aspirin, clopidogrel, or NSAIDs raises bleeding risk. Stop it 1–2 weeks before surgery. People with epilepsy should avoid it, and it can induce CYP enzymes that lower levels of some drugs — check with a pharmacist if you take narrow-margin medications.
References
- 01StatPearls — Ginkgo Biloba (NCBI Bookshelf)
- 02Cochrane — Ginkgo biloba for cognitive impairment and dementia (Birks & Grimley Evans, 2009)
- 03GEM Study — Ginkgo biloba for prevention of dementia (DeKosky et al., 2008, JAMA / PMC)
- 04Examine.com — Ginkgo biloba
Last reviewed2026-05-24